ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 241
Analysis of 84 Patients with IgG4-Related Disease and Malignancy
9:00AM-11:00AM
Abstract Number: 247
ANTI-Interleukin 1 Therapy in FMF Amyloidosis: A Single Center Experience
9:00AM-11:00AM
Abstract Number: 250
Application of the 2016 European Leage Against Rheumatism (EULAR) /American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) Classification Criteria of Macrophage Activation Syndrome in Patients with Adult Onset Still’s Disease
9:00AM-11:00AM
Abstract Number: 265
Characterization of Eye Sarcoidosis with or without Systemic Involvement: Application of Iwos Criteria in an Uveitis Unit
9:00AM-11:00AM
Abstract Number: 237
Characterization of Peripheral Lymphocyte Phenotype in Patients with IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 242
Clinical and Laboratory Features of IgG4-Related Retroperitoneal Fibrosis/Periarteritis in Japan: Retrospective Multicenter Study of 99 Cases
9:00AM-11:00AM
Abstract Number: 257
CNS Manifestations of Patients with Muckle-Wells Syndrome
9:00AM-11:00AM
Abstract Number: 253
Corticosteroid-Free Tocilizumab Monotherapy for Adult Onset Still’s Disease: Results in Six Month
9:00AM-11:00AM
Abstract Number: 252
Cytokine Profiles of Korean Patients with Adult Onset Still’s Disease Treated with Biologic Agents
9:00AM-11:00AM
Abstract Number: 266
Diffuse Idiopathic Skeletal Hyperostosis and Obesity- Is There a Causal Relationship?
9:00AM-11:00AM
Abstract Number: 267
Diffuse Idiopathic Skeletal Hyperostosis: Can We Identify Different Clinicoradiological Patterns?
9:00AM-11:00AM
Abstract Number: 248
Disease Severity and High Attack Frequency Under Colchicine Treatment Is Associated with Increased Carotid Intima Media Thickness in FMF
9:00AM-11:00AM
Abstract Number: 246
Efficacy of Colchicine and IL-1 Inhibitors in Amyloidosis Associated with Familial Mediterranean Fever: A Retrospective Analysis
9:00AM-11:00AM
Abstract Number: 245
Efficacy of Cyclophosphamide Therapy in Idiopathic Retroperitoneal Fibrosis in a Retrospective Monocentric Analysis
9:00AM-11:00AM
Abstract Number: 243
Eosinophilic Angiocentric Fibrosis : A Mimic of Vasculitis in IgG4 Related Disease Spectrum
9:00AM-11:00AM
Abstract Number: 264
Ethnicity-Related Differences in the Clinical Presentation of Sarcoidosis in Spain (SARCOGEAS-SEMI Registry)
9:00AM-11:00AM
Abstract Number: 263
How Does Sarcoidosis Present in Spain? Characteristics at Diagnosis of 979 Patients from the Sarcogeas-SEMI Registry
9:00AM-11:00AM
Abstract Number: 238
Identifying Immunoglobulin G4-Related Disease in Archived Pathological Specimens
9:00AM-11:00AM
Abstract Number: 236
Intrathoracic Manifestations of IgG4-Related Disease: Findings in a Cohort Study from North America
9:00AM-11:00AM
Abstract Number: 244
Leflunomide and Glucocorticoids Combination Therapy for the Induction and Maintenance of Remission in Patients with IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 239
Malignancies in Korean Patients with Immunoglobulin G4-Related Disease
9:00AM-11:00AM
Abstract Number: 249
MiR-204-3p Associates with an Increased Level of IL-6 in Familial Mediterranean Fever By Targeting the PIK3 Signaling Pathway
9:00AM-11:00AM
Abstract Number: 256
Muckle-Wells Syndrome in Chinese Adult Patients
9:00AM-11:00AM
Abstract Number: 254
NLRP12 Autoinflammatory Disease: A Chinese Case Series and Literature Review
9:00AM-11:00AM
Abstract Number: 251
Persistent Pruritic Skin Lesions with Dyskeratotic Cells in Upper Layer of Epidermis Are Specific and Associated with High Levels of Serum IL-18 in Adult-Onset Still’s Disease
9:00AM-11:00AM
Abstract Number: 260
Risk of Cardiovascular Disease Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study
9:00AM-11:00AM
Abstract Number: 259
Rituximab in Refractory Cardiac Sarcoidosis – Single Center Experience
9:00AM-11:00AM
Abstract Number: 255
Safety and Efficacy of Long-Term Canakinumab Therapy in Patients with CAPS: Final Results from Beta-Confident Registry
9:00AM-11:00AM
Abstract Number: 261
Sarcoidosis Is Associated with Increased Risk of Venous Thromboembolism: A Population-Based Study
9:00AM-11:00AM
Abstract Number: 262
Seasonal Variation in Incidence of Sarcoidosis: A Population-Based Study 1976-2013
9:00AM-11:00AM
Abstract Number: 240
The Relationship Between Serum Cholinesterase, Number of Organ Involvement and Fibrotic Markers in Japanese Patients with IgG4-Related Disease
9:00AM-11:00AM
Abstract Number: 258
Unmet Psychosocial Needs in Patients with CAPS

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology